Key Takeaways
- • IM8 achieved $100 million annual run rate in 11 months following its December 2024 launch as a co-branded wellness supplement venture between Prenetics (NASDAQ: PRE) and David Beckham, making it the fastest-growing direct-to-consumer supplements brand on record.
- • IM8 generated $60.1 million in revenue during its first full fiscal year and reached $120 million in annualized recurring revenue (ARR), demonstrating exceptional unit economics with a 4.8x lifetime value-to-customer acquisition cost ratio.
- • Prenetics secured $44 million in growth financing through a capital raise announced in mid-2026, facilitated by Dominari (partially owned by Eric and Donald Trump Jr.), the company's largest shareholder, though the offering structure with warrant layering triggered market concerns and stock dilution.
- • The market is significantly undervaluing the IM8 opportunity, with Prenetics trading at approximately $200 million market capitalization while holding $130 million in cash and Bitcoin, implying an enterprise value of roughly $70 million for the fastest-growing consumer wellness brand, or less than 1x sales.
- • David Beckham's partnership elevated IM8 to billionaire-brand status, with the 92-ingredient supplement formula emphasizing third-party testing and transparency, positioning the venture as a cornerstone of Beckham's personal wealth alongside his Inter Miami investment stake.
Summary
Prenetics, a Nasdaq-listed health sciences company founded in 2014 by Danny Yeung (former CEO of Groupon Asia), has emerged from pandemic-era revenue collapse into a high-growth direct-to-consumer wellness player through its IM8 brand partnership with David Beckham. Originally built on consumer genetic testing for the Asian market, Prenetics pivoted to COVID testing during the pandemic, generating nearly $300 million in revenue by 2021 before the stock plunged 97% as pandemic revenues dried up. The launch of IM8 in December 2024 marked a strategic repositioning toward sustainable consumer revenue streams.
IM8, co-founded by Beckham and Prenetics, operates as a premium supplement brand delivering 16 supplements in a single-drink format. The brand achieved unprecedented growth metrics: $100 million in annual run rate within 11 months of launch, $60.1 million in actual revenue during its first full fiscal year, and $120 million in annualized recurring revenue. The unit economics are compelling, with a 4.8x lifetime value-to-customer acquisition cost ratio—a metric indicating strong profitability and customer retention efficiency. The 92-ingredient formula emphasizes transparency and third-party testing, positioning IM8 within the premium wellness segment.
In July 2026, Prenetics announced a $44 million growth financing round facilitated by Dominari, the company's largest shareholder partially owned by Eric and Donald Trump Jr. The capital raise employed a complex double-layered warrant structure that triggered dilution concerns and contributed to stock volatility at announcement. Despite the fundraising activity, market valuation remains disconnected from operational performance: at $200 million market capitalization with $130 million in cash and Bitcoin holdings, the enterprise value attributed to IM8 stands at approximately $70 million, or less than 1x revenue—a valuation discount that reflects either significant market skepticism or underappreciation of the brand's growth trajectory and unit economics relative to comparable DTC consumer companies.
Beckham's involvement has elevated IM8's market profile and contributed to his billionaire status according to recent Forbes assessment, with the brand's performance alongside his Inter Miami investment stake comprising significant components of his personal wealth accumulation. The venture demonstrates the continuing appeal of celebrity-backed consumer brands in the wellness sector, particularly when paired with operational execution and transparent formulation standards.
IM8, co-founded by Beckham and Prenetics, operates as a premium supplement brand delivering 16 supplements in a single-drink format. The brand achieved unprecedented growth metrics: $100 million in annual run rate within 11 months of launch, $60.1 million in actual revenue during its first full fiscal year, and $120 million in annualized recurring revenue. The unit economics are compelling, with a 4.8x lifetime value-to-customer acquisition cost ratio—a metric indicating strong profitability and customer retention efficiency. The 92-ingredient formula emphasizes transparency and third-party testing, positioning IM8 within the premium wellness segment.
In July 2026, Prenetics announced a $44 million growth financing round facilitated by Dominari, the company's largest shareholder partially owned by Eric and Donald Trump Jr. The capital raise employed a complex double-layered warrant structure that triggered dilution concerns and contributed to stock volatility at announcement. Despite the fundraising activity, market valuation remains disconnected from operational performance: at $200 million market capitalization with $130 million in cash and Bitcoin holdings, the enterprise value attributed to IM8 stands at approximately $70 million, or less than 1x revenue—a valuation discount that reflects either significant market skepticism or underappreciation of the brand's growth trajectory and unit economics relative to comparable DTC consumer companies.
Beckham's involvement has elevated IM8's market profile and contributed to his billionaire status according to recent Forbes assessment, with the brand's performance alongside his Inter Miami investment stake comprising significant components of his personal wealth accumulation. The venture demonstrates the continuing appeal of celebrity-backed consumer brands in the wellness sector, particularly when paired with operational execution and transparent formulation standards.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.